Lockheed Martin Investment Management Co. Grows Stake in Celgene Co. (CELG)

Lockheed Martin Investment Management Co. grew its holdings in Celgene Co. (NASDAQ:CELG) by 40.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,000 shares of the biopharmaceutical company’s stock after purchasing an additional 4,000 shares during the quarter. Lockheed Martin Investment Management Co.’s holdings in Celgene were worth $2,041,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Arcadia Investment Management Corp MI grew its position in shares of Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares during the last quarter. Thompson Davis & CO. Inc. boosted its position in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the last quarter. Guidant Wealth Advisors acquired a new stake in Celgene during the third quarter worth approximately $119,000. Motco boosted its position in Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares during the last quarter. Finally, Balentine LLC boosted its position in Celgene by 83.5% during the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 481 shares during the last quarter. Institutional investors and hedge funds own 79.74% of the company’s stock.

A number of analysts recently issued reports on CELG shares. Mizuho raised their target price on shares of Celgene from $134.00 to $158.00 and gave the stock a “buy” rating in a research report on Friday, September 15th. Jefferies Group restated a “buy” rating and set a $160.00 target price on shares of Celgene in a research report on Friday, September 15th. Robert W. Baird restated a “buy” rating and set a $162.00 target price on shares of Celgene in a research report on Thursday, September 21st. Cantor Fitzgerald restated a “buy” rating and set a $162.00 target price on shares of Celgene in a research report on Tuesday, September 26th. Finally, Morgan Stanley lowered shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $131.18.

Celgene Co. (NASDAQ:CELG) opened at $106.00 on Friday. Celgene Co. has a one year low of $94.55 and a one year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The company has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a PEG ratio of 0.68 and a beta of 1.77.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the firm posted $1.58 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. sell-side analysts forecast that Celgene Co. will post 6.68 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Lockheed Martin Investment Management Co. Grows Stake in Celgene Co. (CELG)” was first posted by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/01/13/lockheed-martin-investment-management-co-grows-stake-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply